XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.4
Note O - Share-based Compensation
9 Months Ended
Dec. 27, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

NOTE O – SHARE-BASED COMPENSATION

 

Total share-based compensation for each of the thirteen-week periods ended December 27, 2020 and December 29, 2019 was $29,000. Total share-based compensation for each of the thirty-nine week periods ended December 27, 2020 and December 29, 2019 was $87,000. Total share-based compensation is included in general and administrative expenses in our accompanying Consolidated Statements of Earnings. As of December 27, 2020, there was $83,000 of unamortized compensation expense related to share-based incentive awards. The Company expects to recognize this expense over approximately eight months, which represents the weighted average remaining requisite service periods for such awards.

 

The Company recognizes compensation cost for unvested stock-based incentive awards on a straight-line basis over the requisite service period. Compensation cost charged to expense under all stock-based incentive awards is as follows (in thousands):

 

  Thirteen weeks ended    Thirty-nine weeks ended 
  

December 27, 2020

  

December 29, 2019

  

December 27, 2020

  

December 29, 2019

 
                 

Stock options

 $21  $21  $64  $64 

Restricted stock

  8   8   23   23 

Total compensation cost

 $29  $29  $87  $87 

 

Stock options:

 

There were no new share-based awards granted during the thirty-nine week period December 27, 2020.

 

During the fiscal year ended March 31, 2019, the Company granted options to purchase 10,000 shares at an exercise price of $89.90 per share, all of which expire five years from the date of grant. All such stock options vest ratably over a three-year period commencing September 12, 2019.

 

Transactions with respect to stock options for the thirty-nine weeks ended December 27, 2020 are as follows:

 

    Shares  

Weighted-

Average

Exercise

Price

  

Weighted-

Average

Remaining

Contractual Life

  

Aggregate

Intrinsic

Value

(in thousands)

 
                 
                 

Options outstanding at March 29, 2020

  10,000  $89.90   3.45   - 

Granted

  -   -   -   - 

Exercised

  -   -   -   - 

Options outstanding at December 27, 2020

  10,000  $89.90   2.71   - 
                 

Options exercisable at December 27, 2020

  6,667  $89.90   2.71   - 

 

Restricted stock:

 

Transactions with respect to restricted stock for the thirty-nine weeks ended December 27, 2020 are as follows:

 

  

Shares

  

 

Weighted-

Average

Grant-date

Fair value

Per share

 

Unvested restricted stock at March 29, 2020

  667  $89.90 

Granted

  -   - 

Vested

  (334) $89.90 

Unvested restricted stock at December 27, 2020

  333  $89.90